作为一种具有高发病率、高死亡率特点的呼吸系统疾病,慢阻肺不仅给患者带来巨大负担,对全球卫生系统而言也是一个巨大挑战。在多种机制的参与下的反复急性加重是慢阻肺患者死亡的原因之一。据统计,约50%的急性加重事件并未报告。频繁的急性加重是慢阻肺全因死亡的独立危险因素,慢阻肺患者一次急性加重入院其5年死亡率为55.2%,两次中重度急性加重,其死亡风险增加至80%。目前慢阻肺急性加重期的诊断及其严重程度的判定缺乏具体的量化性指标,主要依据患者的症状、体征和医生的判断,故感染性炎性标志物对于AECOPD的诊断和治疗至关重要。该文对近年来关于COPD生物标志物的研究进行了综述。As a respiratory disease with high incidence rate and mortality, COPD not only brings huge burden to patients, but also poses a huge challenge to the global health system. Repeated acute exacerbations involving multiple mechanisms are one of the causes of death in patients with chronic obstructive pulmonary disease. According to statistics, about 50% of acute exacerbations are not reported. Frequent acute exacerbations are an independent risk factor for all-cause mortality in patients with chronic obstructive pulmonary disease (COPD). A 5-year mortality rate of 55.2% for COPD patients admitted to the hospital with one acute exacerbation, and an increased risk of death of 80% for patients with two moderate to severe acute exacerbations. At present, there is a lack of specific quantitative indicators for the diagnosis and severity assessment of acute exacerbation of chronic obstructive pulmonary disease (COPD), mainly based on the patient’s symptoms, signs, and the doctor’s judgment. Therefore, infectious inflammatory markers are crucial for the diagnosis and treatment of AECOPD. This article provides a review of recent research on biomarkers for COPD.
